These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38924432)

  • 1. MEK-SHP2 inhibition prevents tibial pseudarthrosis caused by
    Perrin S; Protic S; Bretegnier V; Laurendeau I; de Lageneste OD; Panara N; Ruckebusch O; Luka M; Masson C; Maillard T; Coulpier F; Pannier S; Wicart P; Hadj-Rabia S; Radomska KJ; Zarhrate M; Ménager M; Vidaud D; Topilko P; Parfait B; Colnot C
    Sci Transl Med; 2024 Jun; 16(753):eadj1597. PubMed ID: 38924432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
    Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
    Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
    El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
    J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
    de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
    J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disturbed osteoblastic differentiation of fibrous hamartoma cell from congenital pseudarthrosis of the tibia associated with neurofibromatosis type I.
    Lee DY; Cho TJ; Lee HR; Lee K; Moon HJ; Park MS; Yoo WJ; Chung CY; Choi IH
    Clin Orthop Surg; 2011 Sep; 3(3):230-7. PubMed ID: 21909471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasculopathy in two cases of NF1-related congenital pseudarthrosis.
    Kuorilehto T; Kinnunen P; Nissinen M; Alanne M; Leskelä HV; Lehenkari P; Peltonen J
    Pathol Res Pract; 2006; 202(9):687-90. PubMed ID: 16735097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
    Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
    J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression.
    Leskelä HV; Kuorilehto T; Risteli J; Koivunen J; Nissinen M; Peltonen S; Kinnunen P; Messiaen L; Lehenkari P; Peltonen J
    Bone; 2009 Feb; 44(2):243-50. PubMed ID: 19061981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.
    Paria N; Cho TJ; Choi IH; Kamiya N; Kayembe K; Mao R; Margraf RL; Obermosser G; Oxendine I; Sant DW; Song MH; Stevenson DA; Viskochil DH; Wise CA; Kim HK; Rios JJ
    J Bone Miner Res; 2014 Dec; 29(12):2636-42. PubMed ID: 24932921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implications.
    Ghadakzadeh S; Kannu P; Whetstone H; Howard A; Alman BA
    FASEB J; 2016 Sep; 30(9):3227-37. PubMed ID: 27306335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy.
    Nebesio TD; Ming W; Chen S; Clegg T; Yuan J; Yang Y; Estwick SA; Li Y; Li X; Hingtgen CM; Yang FC
    Glia; 2007 Apr; 55(5):527-36. PubMed ID: 17236191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1.
    Cho TJ; Seo JB; Lee HR; Yoo WJ; Chung CY; Choi IH
    J Bone Joint Surg Am; 2008 Dec; 90(12):2735-44. PubMed ID: 19047720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of tibial fracture healing in normal and Nf1-deficient mice.
    Schindeler A; Morse A; Harry L; Godfrey C; Mikulec K; McDonald M; Gasser JA; Little DG
    J Orthop Res; 2008 Aug; 26(8):1053-60. PubMed ID: 18383150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of NF1 and non-NF1 congenital pseudarthrosis of the tibia based on germline NF1 variants: genetic and clinical analysis of 75 patients.
    Zhu G; Zheng Y; Liu Y; Yan A; Hu Z; Yang Y; Xiang S; Li L; Chen W; Peng Y; Zhong N; Mei H
    Orphanet J Rare Dis; 2019 Sep; 14(1):221. PubMed ID: 31533797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
    Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
    Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.